Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Invests In China Oncology Start-Ip BeiGene

Executive Summary

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

You may also be interested in...



Start-Up Quarterly Statistics, Q2 2011

Funding for biopharma start-ups nearly doubled from Q1 to Q2 2011, with a total of $251 million. The quarter saw increased investment in emerging markets, particularly in China. Biopharma start-ups scored many deals with Big Pharma, in several cases playing the role of licensee. And while M&A activity for the start-up set was limited to two deals, for each of those agreements the start-ups were the ones on the acquiring side scooping up assets from other companies.

ASLAN Completes Series A Funding For $12 Mn; Eyes More Financing Options With Spiraling Portfolio

MUMBAI - Singapore-based discovery research start-up ASLAN Pharmaceuticals reached a major milestone as it completed its Series A financing of $12 million. The fund will be utilized to develop the first set of in-licensed compounds by ASLAN

Is China A Black Swan For Big Pharma? (Part 2 of 2)

[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]

Related Content

Topics

UsernamePublicRestriction

Register

PS053381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel